FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hiroshi Yamazaki

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Microsomes, Liver

Geographic Areas

Japan

Concepts & Ideas

Procedures

Disorders

Lung Neoplasms

Living Beings

Co-author Network

Publications

TOP 3
Tomohisa Nakada; Tetsuya Saito; Takahiko Uno; Keiko Yamakawa; Hiroshi Yamazaki; Masanao Yokohira; Masaki Fujieda; Katsumi Imaida; Shunsuke Iwano; Kazuma Kiyotani; Tetsuya Kamataki
Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway.
Norihito Shibahara; Hiroshi Yamazaki; Shunsuke Iwano; Kazuma Kiyotani; Yuiko Masunaga; Tetsuya Kamataki
Human cytochrome P450 1A1 is a novel target gene of liver X receptor α.
K Murai; Hiroshi Yamazaki; Kazuko Nakagawa; R Kawai; Tetsuya Kamataki
Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hiroshi Yamazaki (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Tomohisa Nakada; Tetsuya Saito; Takahiko Uno; Keiko Yamakawa; Hiroshi Yamazaki; Masanao Yokohira; Masaki Fujieda; Katsumi Imaida; Shunsuke Iwano; Kazuma Kiyotani; Tetsuya Kamataki
Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway.
The Journal of toxicological sciences 2012;37(3):555-63.
2011: Norihito Shibahara; Hiroshi Yamazaki; Shunsuke Iwano; Kazuma Kiyotani; Yuiko Masunaga; Tetsuya Kamataki
Human cytochrome P450 1A1 is a novel target gene of liver X receptor α.
Drug metabolism and pharmacokinetics 2011;26(5):451-7.
2009: K Murai; Hiroshi Yamazaki; Kazuko Nakagawa; R Kawai; Tetsuya Kamataki
Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes.
Xenobiotica; the fate of foreign compounds in biological systems 2009;39(11):795-802.
2009: Masayuki Matsunaga; Hiroshi Yamazaki; Kazuma Kiyotani; Shunsuke Iwano; Jyunji Saruwatari; Kazuko Nakagawa; Akiko Soyama; Shogo Ozawa; Jun-Ichi Sawada; Eiji Kashiyama; Moritoshi Kinoshita; Tetsuya Kamataki
Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(4):699-701.
2006: Sompop Peamkrasatam; Kampon Sriwatanakul; Kazuma Kiyotani; Masaki Fujieda; Hiroshi Yamazaki; Tetsuya Kamataki; Krongtong Yoovathaworn
In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.
Drug metabolism and pharmacokinetics 2006;21(6):475-84.
2005: Masafumi Miyazaki; Hiroshi Yamazaki; Hijiri Takeuchi; Kousuke Saoo; Masanao Yokohira; Ken-ichi Masumura; Takehiko Nohmi; Yoshihiko Funae; Katsumi Imaida; Tetsuya Kamataki
Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas.
Carcinogenesis 2005;26(11):1947-55.
2005: Miyuki Kimura; Hiroshi Yamazaki; Masaki Fujieda; Kazuma Kiyotani; Goro Honda; Junji Saruwatari; Kazuko Nakagawa; Takashi Ishizaki; Tetsuya Kamataki
Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(9):1361-6.
2005: Masafumi Miyazaki; Eika Sugawara; Teruki Yoshimura; Hiroshi Yamazaki; Tetsuya Kamataki
Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108.
Mutation research 2005;581(1-2):165-71.
2005: Maxwell Afari Gyamfi; Masaki Fujieda; Kazuma Kiyotani; Hiroshi Yamazaki; Tetsuya Kamataki
High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana.
European journal of clinical pharmacology 2005;60(12):855-7.
2005: Satoshi Yamaori; Hiroshi Yamazaki; Shunsuke Iwano; Kazuma Kiyotani; Keiko Matsumura; Tetsuya Saito; Andrew Parkinson; Kazuko Nakagawa; Tetsuya Kamataki
Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.
Xenobiotica; the fate of foreign compounds in biological systems 2005;35(1):69-83.
2004: Masaki Fujieda; Hiroshi Yamazaki; Tetsuya Saito; Kazuma Kiyotani; Maxwell Afari Gyamfi; Masaharu Sakurai; Hirotoshi Dosaka-Akita; Yuichi Sawamura; Jun Yokota; Hideo Kunitoh; Tetsuya Kamataki
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
Carcinogenesis 2004;25(12):2451-8.
2004: Yoshiyuki Yamazaki; Ken-Ichi Fujita; Kazuo Nakayama; Akihiro Suzuki; Katsunori Nakamura; Hiroshi Yamazaki; Tetsuya Kamataki
Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens.
Mutation research 2004;562(1-2):151-62.
2004: Hiroshi Yamazaki; Masaki Fujieda; Masahiro Togashi; Tetsuya Saito; George Preti; John R Cashman; Tetsuya Kamataki
Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients.
Life sciences 2004;74(22):2739-47.
2004: Satoshi Yamaori; Hiroshi Yamazaki; Shunsuke Iwano; Kazuma Kiyotani; Keiko Matsumura; Goro Honda; Kazuko Nakagawa; Takashi Ishizaki; Tetsuya Kamataki
CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Drug metabolism and pharmacokinetics 2004;19(2):120-9.
2004: Kenji Toide; Yoshiaki Terauchi; Toshihiko Fujii; Hiroshi Yamazaki; Tetsuya Kamataki
Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes.
Biochemical pharmacology 2004;67(7):1269-78.
2004: Keiko Matsumura; Tetsuya Saito; Yoshiki Takahashi; Takeshi Ozeki; Kazuma Kiyotani; Masaki Fujieda; Hiroshi Yamazaki; Hideo Kunitoh; Tetsuya Kamataki
Identification of a novel polymorphic enhancer of the human CYP3A4 gene.
Molecular pharmacology 2004;65(2):326-34.
2003: Satoshi Yamaori; Hiroshi Yamazaki; Akihiro Suzuki; Ayako Yamada; Hirofumi Tani; Tamio Kamidate; Ken ichi Fujita; Tetsuya Kamataki
Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.
Biochemical pharmacology 2003;66(12):2333-40.
2003: Hijiri Takeuchi; Kousuke Saoo; Masanao Yokohira; Mico Ikeda; Hajime Maeta; Masafumi Miyazaki; Hiroshi Yamazaki; Tetsuya Kamataki; Katsumi Imaida
Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.
Cancer research 2003;63(22):7581-3.
2003: Kazuma Kiyotani; Hiroshi Yamazaki; Masaki Fujieda; Shunsuke Iwano; Keiko Matsumura; Soisungwan Satarug; Pailin Ujjin; Tsutomu Shimada; F Peter Guengerich; Andrew Parkinson; Goro Honda; Kazuko Nakagawa; Takashi Ishizaki; Tetsuya Kamataki
Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).
Pharmacogenetics 2003;13(11):689-95.
2003: Kenji Toide; Hiroshi Yamazaki; Rikako Nagashima; Keisuke Itoh; Shunsuke Iwano; Yoshiki Takahashi; Shaw Watanabe; Tetsuya Kamataki
Aryl hydrocarbon hydroxylase represents CYP1B1, and not CYP1A1, in human freshly isolated white cells: trimodal distribution of Japanese population according to induction of CYP1B1 mRNA by environmental dioxins.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2003;12(3):219-22.
2003: Masaki Fujieda; Hiroshi Yamazaki; Masahiro Togashi; Tetsuya Saito; Tetsuya Kamataki
Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese.
Drug metabolism and pharmacokinetics 2003;18(5):333-5.
2003: Hiroshi Yamazaki; Kazuma Kiyotani; Satoshi Tsubuko; Masayuki Matsunaga; Masaki Fujieda; Tetsuya Saito; Jun Miura; Shinichi Kobayashi; Tetsuya Kamataki
Two novel haplotypes of CYP2D6 gene in a Japanese population.
Drug metabolism and pharmacokinetics 2003;18(4):269-71.
2003: Tetsuya Saito; Mari Egashira; Kazuma Kiyotani; Masaki Fujieda; Hiroshi Yamazaki; Chikako Kiyohara; Hideo Kunitoh; Tetsuya Kamataki
Novel nonsynonymous polymorphisms of the CYP1A1 gene in Japanese.
Drug metabolism and pharmacokinetics 2003;18(3):218-21.
2003: Masaki Fujieda; Hiroshi Yamazaki; Kazuma Kiyotani; Asami Muroi; Hideo Kunitoh; Hirotoshi Dosaka-Akita; Yuichi Sawamura; Tetsuya Kamataki
Eighteen novel polymorphisms of the CYP2A13 gene in Japanese.
Drug metabolism and pharmacokinetics 2003;18(1):86-90.
2002: Junji Saruwatari; Kazuko Nakagawa; Junichi Shindo; Takahiro Tajiri; Masaki Fujieda; Hiroshi Yamazaki; Tetsuya Kamataki; Takashi Ishizaki
A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test.
Clinical pharmacology and therapeutics 2002;72(2):200-8.
2002: Satoshi Daigo; Yoshiki Takahashi; Masaki Fujieda; Noritaka Ariyoshi; Hiroshi Yamazaki; Wasaburo Koizumi; Satoshi Tanabe; Katsunori Saigenji; Sekio Nagayama; Kazumasa Ikeda; Yasuhiko Nishioka; Tetsuya Kamataki
A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Pharmacogenetics 2002;12(4):299-306.
2002: Kenji Toide; Yoshiki Takahashi; Hiroshi Yamazaki; Yoshiaki Terauchi; Toshihiko Fujii; Andrew Parkinson; Tetsuya Kamataki
Hepatocyte nuclear factor-1alpha is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):613-5.
2002: Hiroshi Yamazaki; Tetsuya Kamataki
[P450 and carcinogenesis].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 2002;119(4):208-12.
2002: Zeki Topcu; Itsuo Chiba; Masaki Fujieda; Toshiyuki Shibata; Noritaka Ariyoshi; Hiroshi Yamazaki; Figen Sevgican; Malsantha Muthumala; Hiroshi Kobayashi; Tetsuya Kamataki
CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka.
Carcinogenesis 2002;23(4):595-8.
2002: Pailin Ujjin; Soisungwan Satarug; Yuvaree Vanavanitkun; Satoshi Daigo; Noritaka Ariyoshi; Hiroshi Yamazaki; Paul E B Reilly; Michael R Moore; Tetsuya Kamataki
Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females.
Pharmacogenetics 2002;12(3):241-9.
2002: Kazuma Kiyotani; Masaki Fujieda; Hiroshi Yamazaki; Tsutomu Shimada; F Peter Guengerich; Andrew Parkinson; Kazuko Nakagawa; Takashi Ishizaki; Tetsuya Kamataki
Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians.
Drug metabolism and pharmacokinetics 2002;17(5):482-7.
2002: Kenji Toide; Shin-Ichiro Umeda; Hiroshi Yamazaki; Yoshiki Takahashi; Yoshiaki Terauchi; Toshihiko Fujii; Tetsuya Kamataki
A major genotype in UDP-glucuronosyltransferase 2B15.
Drug metabolism and pharmacokinetics 2002;17(2):164-6.
2002: Kazuma Kiyotani; Hiroshi Yamazaki; Masaki Fujieda; Satoshi Daigo; Soisungwan Satarug; Pailin Ujjin; Tetsuya Kamataki
Novel mutations of the CYP2A6 gene in a Thai population with lowered capacity of coumarin 7-hydroxylation.
Drug metabolism and pharmacokinetics 2002;17(2):161-3.